129 filings
Page 4 of 7
8-K
cj2n54q
9 May 22
Inhibrx Reports First Quarter 2022 Financial Results
4:10pm
8-K
w12 byausulvakc0i0zz
25 Apr 22
Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101
9:04am
DEFA14A
tpsg4s8o
13 Apr 22
Additional proxy soliciting materials
4:09pm
8-K
ez1c d4lot
5 Apr 22
Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting
4:32pm
8-K
v3r1svsfoux igo
4 Apr 22
Regulation FD Disclosure
4:06pm
8-K
mm2ee66cduriacae0
3 Mar 22
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
9:22am
S-8
39uaf l61fq7ostynm6
1 Mar 22
Registration of securities for employees
10:00pm
8-K
a1d9rt 2j1892g87b
28 Feb 22
Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results
4:12pm
8-K
d83pq5
22 Feb 22
Inhibrx Announces Amended Loan Agreement with Oxford
9:11am
8-K
sa8u9j4
25 Jan 22
Departure of Directors or Certain Officers
12:00am
8-K
o0v0qh5gqp2rso9wg
4 Jan 22
Regulation FD Disclosure
4:41pm
8-K
5i4lwiaw27bgr
1 Dec 21
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma
4:07pm
8-K
dit olf497spbxrh
9 Nov 21
Inhibrx Reports Third Quarter 2021 Financial Results
4:37pm
8-K
a0ad9u0czfwopcwjg
28 Oct 21
Departure of Directors or Certain Officers
8:50am
8-K
u89sh5o
12 Oct 21
Regulation FD Disclosure
7:50am
8-K
el4gi
3 Sep 21
Entry into a Material Definitive Agreement
4:33pm